Cargando…

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1

Background: Autism Spectrum Disorder (ASD or autism) is characterized by difficulties in social communication and interaction, which negatively impact on individuals and their families' quality of life. Currently no pharmacological interventions have been shown to be effective for improving soc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parellada, Mara, San José Cáceres, Antonia, Palmer, Melanie, Delorme, Richard, Jones, Emily J. H., Parr, Jeremy R., Anagnostou, Evdokia, Murphy, Declan G. M., Loth, Eva, Wang, Paul P., Charman, Tony, Strydom, Andre, Arango, Celso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421761/ https://www.ncbi.nlm.nih.gov/pubmed/34504446 http://dx.doi.org/10.3389/fpsyt.2021.701729

Ejemplares similares

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

A MEG Study of Acute Arbaclofen (STX-209) Administration
por: Roberts, Timothy P. L., et al.
Publicado: (2019)

Investigating the factors underlying adaptive functioning in autism in the EU‐AIMS Longitudinal European Autism Project
por: Tillmann, Julian, et al.
Publicado: (2019)

Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder
por: Frye, Richard E
Publicado: (2014)

Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis
por: Siafis, Spyridon, et al.
Publicado: (2020)

Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2022)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
por: Okuda, Darin T, et al.
Publicado: (2023)

Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
por: Siafis, Spyridon, et al.
Publicado: (2021)

Towards Preclinical Validation of Arbaclofen (R-baclofen) Treatment for 16p11.2 Deletion Syndrome
por: Gundersen, Brigitta B., et al.
Publicado: (2023)

Autism with co-occurring epilepsy care pathway in Europe
por: Mendez, Maria A., et al.
Publicado: (2023)

How do core autism traits and associated symptoms relate to quality of life? Findings from the Longitudinal European Autism Project
por: Oakley, Bethany FM, et al.
Publicado: (2020)

Autism care pathway in Europe
por: Mendez, Maria A., et al.
Publicado: (2023)

Modeling flexible behavior in childhood to adulthood shows age-dependent learning mechanisms and less optimal learning in autism in each age group
por: Crawley, Daisy, et al.
Publicado: (2020)

Arbaclofen Placarbil Decreases Reflux With Good Tolerability in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2010;105:1266-1275)
por: Kim, Gwang Ha
Publicado: (2010)

Gray matter covariations and core symptoms of autism: the EU-AIMS Longitudinal European Autism Project
por: Mei, Ting, et al.
Publicado: (2020)

The Synaptic Gene Study: Design and Methodology to Identify Neurocognitive Markers in Phelan-McDermid Syndrome and NRXN1 Deletions
por: Cooke, Jennifer, et al.
Publicado: (2022)

Characterisation of the clinical phenotype in Phelan-McDermid syndrome
por: Burdeus-Olavarrieta, Mónica, et al.
Publicado: (2021)

Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
por: McCracken, James T., et al.
Publicado: (2021)

EU-AIMS Longitudinal European Autism Project (LEAP): the autism twin cohort
por: Isaksson, Johan, et al.
Publicado: (2018)

Predictors of outcome in early-onset psychosis: a systematic review
por: Díaz-Caneja, Covadonga M, et al.
Publicado: (2015)

Linking functional and structural brain organisation with behaviour in autism: a multimodal EU-AIMS Longitudinal European Autism Project (LEAP) study
por: Oblong, Lennart M., et al.
Publicado: (2023)

The impact of COVID-19 lockdown on child and adolescent mental health: systematic review
por: Panchal, Urvashi, et al.
Publicado: (2021)

Care pathway for autistic children and their families in Europe
por: Mendez, M.A., et al.
Publicado: (2022)

The meaning of significant mean group differences for biomarker discovery
por: Loth, Eva, et al.
Publicado: (2021)

The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation
por: Charman, Tony, et al.
Publicado: (2017)

T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA
por: Pina-Camacho, Laura, et al.
Publicado: (2020)

T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT
por: Santonja, Javier, et al.
Publicado: (2020)

Alexithymia in autism: cross-sectional and longitudinal associations with social-communication difficulties, anxiety and depression symptoms
por: Oakley, Bethany F. M., et al.
Publicado: (2022)

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
por: Mullen, Michael, et al.
Publicado: (2019)

Role of cortical excitatory/inhibitory imbalance in autism spectrum disorders from a symptom severity trajectories framework: a study protocol
por: Colomar, Laura, et al.
Publicado: (2023)

Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program
por: Belkora, Jeff, et al.
Publicado: (2015)

In-depth characterization of neuroradiological findings in a large sample of individuals with autism spectrum disorder and controls
por: Ambrosino, Sara, et al.
Publicado: (2022)

Evaluation of data imputation strategies in complex, deeply-phenotyped data sets: the case of the EU-AIMS Longitudinal European Autism Project
por: Llera, A., et al.
Publicado: (2022)

Analysis of common genetic variation across targets of microRNAs dysregulated both in ASD and epilepsy reveals negative correlation
por: Stella, Carol, et al.
Publicado: (2023)

Biodistribution and Molecular Studies on Orally Administered Nanoparticle-AON Complexes Encapsulated with Alginate Aiming at Inducing Dystrophin Rescue in mdx Mice
por: Falzarano, Maria Sofia, et al.
Publicado: (2013)

Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda
por: Nunn, Andrew, et al.
Publicado: (2016)

Aiming towards hepatitis C virus elimination in Greece
por: Papatheodoridis, George V., et al.
Publicado: (2019)

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders
por: Loth, Eva, et al.
Publicado: (2017)

Evaluation of measurement properties of self-administered PROMs aimed at patients with non-specific shoulder pain and “activity limitations”: a systematic review
por: Thoomes-de Graaf, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e6b6mk4pastotgfre76ja4sflh